Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. Class A

Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. Class A

SSZSE:300534
8.91
CNY
-0.64
(-6.70%)
0.15EPS
155.29P/E
3.82BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. Class A carries a market capitalization of 3.82B, placing it among publicly traded companies globally. Its enterprise value stands at 3.83B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.82B
Enterprise Value3.83B

Share Statistics

As of September 30, 2026, Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. Class A has 303.35M shares outstanding.

Shares Outstanding303.35M

Valuation Ratios

As of September 30, 2026, Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 155.29. The price-to-sales ratio is 5.37, and the price-to-book ratio stands at 5.41.

PE Ratio155.29
PS Ratio5.37
PB Ratio5.41
P/TBV Ratio6.15

Enterprise Valuation

As of September 30, 2026, Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. Class A trades at an EV/EBITDA multiple of 55.57 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.39 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 55.57 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.83B versus a market cap of 3.82B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales5.39
EV / EBITDA55.57
EV / EBIT55.57

Financial Position

As of September 30, 2026, Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. Class A maintains a current ratio of 1.60, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 17.61, indicating elevated leverage, while an interest coverage ratio of 27.59 demonstrates strong ability to service its debt obligations.

Current Ratio1.60
Quick Ratio0.57
Debt / Equity17.61
Debt / EBITDA2.02
Interest Coverage27.59

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. Class A posted a return on equity (ROE) of 3.53, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.46 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.87, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 0.67, useful for judging operating efficiency across full business cycles. The company generates approximately 1.11M in revenue per employee across its workforce of 641.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)3.53
Return on Assets (ROA)1.87
Return on Invested Capital (ROIC)5.46
Return on Capital Employed (ROCE)0.67
Revenue Per Employee1.11M
Employee Count641.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. Class A recorded 21.82M in income tax expense. That works out to an effective tax rate of 32.54, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 67.05M, leaving 24.57M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax21.82M
Effective Tax Rate32.54

Stock Price Statistics

CNY

As of the close on November 17, 2026, Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. Class A's stock has declined approximately 16.18% over the past 52 weeks. The 50-day moving average sits at 11.62, while the 200-day moving average is 10.70.

52-Week Price Change-16.18%
50-Day Moving Average11.62
200-Day Moving Average10.70

Income Statement

CNY

Over the twelve months ended September 30, 2026, Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. Class A generated 710.26M in revenue and converted that into 24.57M in net income, yielding earnings per share of 0.15. EBITDA reached 68.92M, while operating income came in at 77.17M.

Revenue710.26M
Gross Profit466.67M
Operating Income77.17M
Pretax Income67.05M
Net Income24.57M
EBITDA68.92M
EBIT68.92M
Earnings Per Share (EPS)0.15

Balance Sheet

CNY

As of September 30, 2026, Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. Class A holds 210.76M in cash and equivalents against 139.25M in total debt, resulting in a net debt position of -87.07M. Total book value stands at 705.36M, with working capital of 222.77M providing operational flexibility.

Cash & Cash Equivalents210.76M
Total Debt139.25M
Net Debt-87.07M
Equity (Book Value)705.36M
Book Value Per Share2.33
Working Capital222.77M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-27.66M

Margins

Over the twelve months ended September 30, 2026, Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. Class A posted a gross margin of 65.70, reflecting its pricing power and cost economics. The operating margin of 10.87 and net profit margin of 3.46 provide insight into operational efficiency.

Gross Margin65.70
Operating Margin10.87
Pretax Margin9.44
Profit Margin3.46
EBITDA Margin9.70

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. Class A paid dividends of 0.03 per share. The dividend payout ratio of 13.10 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.88, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. Class A shareholders.

Dividend Per Share0.03
Payout Ratio13.10
Shareholder Yield0.88

Stock Splits

Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. Class A's most recent stock split took place on May 10, 2017 with a 20:91 split ratio.

Last Split Date5/10/2017
Split Ratio20:91

Scores

As of September 30, 2026, Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. Class A has an Altman Z-Score of 5.70, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.70